182 related articles for article (PubMed ID: 17630352)
1. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma.
Niens M; Jarrett RF; Hepkema B; Nolte IM; Diepstra A; Platteel M; Kouprie N; Delury CP; Gallagher A; Visser L; Poppema S; te Meerman GJ; van den Berg A
Blood; 2007 Nov; 110(9):3310-5. PubMed ID: 17630352
[TBL] [Abstract][Full Text] [Related]
2. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma.
Hjalgrim H; Rostgaard K; Johnson PC; Lake A; Shield L; Little AM; Ekstrom-Smedby K; Adami HO; Glimelius B; Hamilton-Dutoit S; Kane E; Taylor GM; McConnachie A; Ryder LP; Sundstrom C; Andersen PS; Chang ET; Alexander FE; Melbye M; Jarrett RF
Proc Natl Acad Sci U S A; 2010 Apr; 107(14):6400-5. PubMed ID: 20308568
[TBL] [Abstract][Full Text] [Related]
3. Human leukocyte antigens and genetic susceptibility to lymphoma.
McAulay KA; Jarrett RF
Tissue Antigens; 2015 Aug; 86(2):98-113. PubMed ID: 26189878
[TBL] [Abstract][Full Text] [Related]
4. Genetic susceptibility to Hodgkin's lymphoma associated with the human leukocyte antigen region.
Diepstra A; Niens M; te Meerman GJ; Poppema S; van den Berg A
Eur J Haematol Suppl; 2005 Jul; (66):34-41. PubMed ID: 16007866
[TBL] [Abstract][Full Text] [Related]
5. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma.
Diepstra A; Niens M; Vellenga E; van Imhoff GW; Nolte IM; Schaapveld M; van der Steege G; van den Berg A; Kibbelaar RE; te Meerman GJ; Poppema S
Lancet; 2005 Jun 25-Jul 1; 365(9478):2216-24. PubMed ID: 15978930
[TBL] [Abstract][Full Text] [Related]
6. Modeling HLA associations with EBV-positive and -negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis.
Johnson PC; McAulay KA; Montgomery D; Lake A; Shield L; Gallagher A; Little AM; Shah A; Marsh SG; Taylor GM; Jarrett RF
Int J Cancer; 2015 Sep; 137(5):1066-75. PubMed ID: 25648508
[TBL] [Abstract][Full Text] [Related]
7. Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups.
Huang X; Kushekhar K; Nolte I; Kooistra W; Visser L; Bouwman I; Kouprie N; Veenstra R; van Imhoff G; Olver B; Houlston RS; Poppema S; Diepstra A; Hepkema B; van den Berg A
Blood; 2011 Nov; 118(19):5211-7. PubMed ID: 21921049
[TBL] [Abstract][Full Text] [Related]
8. HLA expression and HLA type associations in relation to EBV status in Hispanic Hodgkin lymphoma patients.
Fletcher LB; Veenstra RN; Loo EY; Hwang AE; Siddiqi IN; Visser L; Hepkema BG; Nolte IM; van den Berg A; Cozen W; Diepstra A
PLoS One; 2017; 12(3):e0174457. PubMed ID: 28334025
[TBL] [Abstract][Full Text] [Related]
9. HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02.
Martín P; Krsnik I; Navarro B; Provencio M; García JF; Bellas C; Vilches C; Gomez-Lozano N
PLoS One; 2015; 10(8):e0135512. PubMed ID: 26261988
[TBL] [Abstract][Full Text] [Related]
10. The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes.
Niens M; van den Berg A; Diepstra A; Nolte IM; van der Steege G; Gallagher A; Taylor GM; Jarrett RF; Poppema S; te Meerman GJ
Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2280-4. PubMed ID: 17119058
[TBL] [Abstract][Full Text] [Related]
11. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
Kinch A; Sundström C; Tufveson G; Glimelius I
Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation patterns in EBV-positive and EBV-negative Hodgkin lymphomas.
Dhiab MB; Ziadi S; Mestiri S; Gacem RB; Ksiaa F; Trimeche M
Cell Oncol (Dordr); 2015 Dec; 38(6):453-62. PubMed ID: 26350502
[TBL] [Abstract][Full Text] [Related]
13. HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China.
Huang X; Hepkema B; Nolte I; Kushekhar K; Jongsma T; Veenstra R; Poppema S; Gao Z; Visser L; Diepstra A; van den Berg A
PLoS One; 2012; 7(2):e31865. PubMed ID: 22355400
[TBL] [Abstract][Full Text] [Related]
14. A Novel Risk Locus at 6p21.3 for Epstein-Barr Virus-Positive Hodgkin Lymphoma.
Delahaye-Sourdeix M; Urayama KY; Gaborieau V; Veenstra R; Foll M; Chabrier A; Benavente Y; Nieters A; Becker N; Foretova L; Maynadié M; Staines A; Smedby KE; Glimelius I; Lightfoot T; Cocco P; Galan P; Vatten LJ; Duell EJ; Kiemeney L; Roman E; de Sanjosé S; Lathrop M; Melbye M; Brennan P; Diepstra A; van den Berg A; Hjalgrim H; Jarrett RF; McKay JD
Cancer Epidemiol Biomarkers Prev; 2015 Dec; 24(12):1838-43. PubMed ID: 26404960
[TBL] [Abstract][Full Text] [Related]
15. The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.
Jones K; Wockner L; Brennan RM; Keane C; Chattopadhyay PK; Roederer M; Price DA; Cole DK; Hassan B; Beck K; Gottlieb D; Ritchie DS; Seymour JF; Vari F; Crooks P; Burrows SR; Gandhi MK
Clin Exp Immunol; 2016 Feb; 183(2):206-20. PubMed ID: 26422112
[TBL] [Abstract][Full Text] [Related]
16. HLA associations in classical Hodgkin lymphoma: EBV status matters.
Huang X; Kushekhar K; Nolte I; Kooistra W; Visser L; Bouwman I; Kouprie N; Veenstra R; van Imhoff G; Olver B; Houlston RS; Poppema S; Diepstra A; Hepkema B; van den Berg A
PLoS One; 2012; 7(7):e39986. PubMed ID: 22808081
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of risk factors and antibody profiles in epstein-barr virus genome-positive and -negative hodgkin lymphoma.
Chang ET; Zheng T; Lennette ET; Weir EG; Borowitz M; Mann RB; Spiegelman D; Mueller NE
J Infect Dis; 2004 Jun; 189(12):2271-81. PubMed ID: 15181575
[TBL] [Abstract][Full Text] [Related]
18. Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients.
Spacek M; Hubacek P; Markova J; Zajac M; Vernerova Z; Kamaradova K; Stuchly J; Kozak T
APMIS; 2011 Jan; 119(1):10-6. PubMed ID: 21143522
[TBL] [Abstract][Full Text] [Related]
19. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus infection and single nucleotide polymorphisms in the promoter region of interleukin 10 gene in patients with Hodgkin lymphoma.
da Silva GN; Bacchi MM; Rainho CA; de Oliveira DE
Arch Pathol Lab Med; 2007 Nov; 131(11):1691-6. PubMed ID: 17979488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
